---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Dosage"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Dosage. Topics: Phase 3 regimen: 1-week run-in dose followed by the target dose, with no dose reduction; Company statement on dose adjustment for tolerability in clinical practice; Atomoxetine dose relative to the maximum recommended ADHD dose; Higher aroxybutynin dose (5/75 mg) in dose finding (MARIPOSA). 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/dosage"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Phase 3 regimen: 1-week run-in dose followed by the target dose, with no dose reduction

> “AD109 dose was aroxybutynin 2.5 mg/atomoxetine 37.5 mg for week 1 and aroxybutynin 2.5 mg/atomoxetine 75 mg for the remaining weeks (dose reductions not permitted).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

> “The IMP is dispensed as a blister package of 7 run-in dose tablets and a bottle containing 33 target dose tablets.”
> “Dose reduction is not permitted, and dosing is discontinued if the participant experiences intolerance to the assigned study drug.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.10.1-2"></a>

### Company statement on dose adjustment for tolerability in clinical practice

> “A lower dose of AD109 (2.3/37.5mg) was administered during the one-week run-in period; however, dose reduction was not permitted in the Phase 3 trials, to maximize evaluation of efficacy. The same lower dose demonstrated improvements in AHI in a prior trial in milder OSA (Figure 9). We believe dose adjustment may be considered in clinical practice, if AD109 is approved, to address tolerability.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “In addition, participants who experienced a higher incidence of AEs may have benefited from a lower, efficacious dose of AD109.30 However, dose reduction was not allowed in the trial.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.10.1-3"></a>

### Atomoxetine dose relative to the maximum recommended ADHD dose

> “The highest dose of atomoxetine that is being considered for Oxnimbi is 75mg, which is lower than the maximum recommended dose for ADHD of 100mg per day.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.10.1-4"></a>

### Higher aroxybutynin dose (5/75 mg) in dose finding (MARIPOSA)

> “It is unclear why we did not see improvement with the higher dose of AD109, although higher rates of daytime symptoms such as dry mouth, urinary hesitation, constipation, and somnolence were reported with the higher dose of aroxybutynin, suggesting more tolerability issues with the AD109 5/75 mg dose.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
